Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $261M | $26.4M | $70.1M | $128M | $156M | $156M | $187M | $236M | $285M | $357M |
| Revenue growth | — | -89.9% | 165.4% | 82.6% | 21.9% | -0.3% | 20.0% | 26.5% | 20.5% | 25.4% |
| Net income | $70.3M | $158M | $279M | $69.0M | $138M | -$113M | -$77.6M | $13.8M | $127M | $156M |
| Net margin | 27.0% | 599.3% | 397.9% | 53.9% | 88.7% | -72.8% | -41.6% | 5.8% | 44.5% | 43.6% |
| EPS (diluted) | $0.92 | $1.40 | $1.51 | $0.37 | $0.67 | -$0.52 | -$0.34 | $0.06 | $0.54 | $0.64 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $176M | $136M | $361M | $372M | $355M | $356M | $316M | $301M | $311M | $349M |
| Dividends paid | $119M | $182M | $325M | $335M | $278M | $263M | $277M | $277M | $280M | $289M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $25.7M | $519M | $50.2M | $39.1M | $59.1M | $112M | $49.3M | $41.3M | $60.5M | $71.5M |
| Total assets | $2.27B | $7.03B | $6.67B | $6.07B | $5.99B | $5.97B | $5.75B | $5.39B | $5.30B | $5.49B |
| Total liabilities | $1.25B | $3.60B | $3.41B | $2.58B | $2.58B | $2.59B | $2.69B | $2.58B | $2.56B | $2.67B |
| Long-term debt | $1.21B | $3.39B | $3.23B | $2.40B | $2.37B | $2.39B | $2.51B | $2.41B | $2.42B | $2.53B |
| Shareholders' equity | $1.02B | $3.43B | $3.25B | $3.49B | $3.41B | $3.38B | $3.06B | $2.80B | $2.74B | $2.82B |
| Shares (wtd avg diluted) | 65.5M | 106M | 179M | 188M | 207M | 219M | 231M | 233M | 236M | 244M |
Every figure is extracted from Sabra Health Care REIT, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.